Bristol-Myers Squibb Company - Product Pipeline Review - 2016

  • ID: 3691126
  • Company Profile
  • 255 pages
  • Global Markets Direct
  • Bristol-Myers Squibb
1 of 4
Bristol-Myers Squibb Company - Product Pipeline Review - 2016

Summary

‘Bristol-Myers Squibb Company - Product Pipeline Review - 2016’, provides an overview of the Bristol-Myers Squibb Company’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Bristol-Myers Squibb Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Bristol-Myers Squibb Company
- The report provides overview of Bristol-Myers Squibb Company including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Bristol-Myers Squibb Company’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Bristol-Myers Squibb Company’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Bristol-Myers Squibb Company’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bristol-Myers Squibb Company
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bristol-Myers Squibb Company’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Bristol-Myers Squibb Company Snapshot

Bristol-Myers Squibb Company Overview

Key Information

Key Facts

Bristol-Myers Squibb Company - Research and Development Overview

Key Therapeutic Areas

Bristol-Myers Squibb Company - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Bristol-Myers Squibb Company - Pipeline Products Glance

Bristol-Myers Squibb Company - Late Stage Pipeline Products

Bristol-Myers Squibb Company - Clinical Stage Pipeline Products

Bristol-Myers Squibb Company - Early Stage Pipeline Products

Bristol-Myers Squibb Company - Drug Profiles

nivolumab

daclatasvir dihydrochloride + asunaprevir

abatacept

apixaban

beclabuvir hydrochloride

brivanib alaninate

ipilimumab

ulocuplumab

BMS-394136

BMS-754807

BMS-833923

BMS-919373

BMS-986020

BMS-986036

BMS-986142

CXL-1427

dasatinib

lirilumab

lulizumab pegol

Recombinant Protein to Antagonize Fibroblast Growth Factor Receptor for Fibrosis

urelumab

BMS-986004

BMS-986012

BMS-986016

BMS-986089

BMS-986148

BMS-986156

BMS-986158

TD-139

Antibody to Target CD40 Ligand for Immunology

Biologic to Inhibit PD-L1 for Immunology

BMS-262084

BMS-777607

BMS-813160

BMS-906024

BMS-963272

BMS-986090

BMS-986104

BMS-986115

BMS-986120

BMS-986141

BMS-986147

BMS-986165

BMS-986168

BMS-986171

BMS-986186

FLX-925

KOS-1803

Recombinant Protein 1 to Antagonize Fibroblast Growth Factor Receptor for Fibrosis

Small Molecule for Oncology

Small Molecule to Antagonize PAR4 for Thromboembolic Disorders

Small Molecule to Inhibit BTK for Immunology

Small Molecule to Inhibit MGAT2 for Type 2 Diabetes and Obesity

Small Molecule to Inhibit TYK2 for Immunology

BMS-817378

ALB-109780

AMR-2

ARX-720

BMS-457

BMS-593214

BMS-654457

BMS-751324

BMS-795311

BMS-816106

BMS-869780

BMS-871

BMS-884775

BMS-986177

BMS-986195

BMS-986205

CXL-1036

Drug for Metabolic Disorders

Drugs to Agonize FPR-2 for Inflammation

DT-1154

F-001287

NP-11948

Small Molecule 2 to Inhibit Factor XIa for Thrombosis

Small Molecule for Pulmonary Arterial Hypertension

Small Molecule to Activate Kv7.2 for Neuropathic Pain and Diabetic Neuropathy

Small Molecule to Antagonize Neuropeptide Y Receptor Y1 for Obesity

Small Molecule to Antagonize NK1R and Block SERT for Depression

Small Molecule to Inhibit IAP for Melanoma

Small Molecule to Inhibit NS5B for Hepatitis C

Small Molecule to Inhibit XIAP and c-IAP for Melanoma

Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease

Small Molecules to Inhibit ROR-Gamma for Inflammation

Monoclonal Antibody Conjugates for Oncology

Proteins for Immunology and Oncology

Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia

Small Molecules to Antagonize Calcitonin Gene-Related Peptide for Migraine

Small Molecules to Antagonize CCR2

Small Molecules to Inhibit IDO and TDO for Oncology

Small Molecules to Inhibit IDO for Oncology

Small Molecules to Inhibit JAK 3 for Inflammation and Autoimmune Diseases

Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders

Small Molecules to Inhibit TDO for Oncology

Bristol-Myers Squibb Company - Pipeline Analysis

Bristol-Myers Squibb Company - Pipeline Products by Target

Bristol-Myers Squibb Company - Pipeline Products by Route of Administration

Bristol-Myers Squibb Company - Pipeline Products by Molecule Type

Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action

Bristol-Myers Squibb Company - Recent Pipeline Updates

Bristol-Myers Squibb Company - Dormant Projects

Bristol-Myers Squibb Company - Dormant Projects

Bristol-Myers Squibb Company - Discontinued Pipeline Products

Bristol-Myers Squibb Company - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Bristol-Myers Squibb Company - Company Statement

Bristol-Myers Squibb Company - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Bristol-Myers Squibb Company - Key Manufacturing Facilities

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Bristol-Myers Squibb Company, Key Information

Bristol-Myers Squibb Company, Key Facts

Bristol-Myers Squibb Company - Pipeline by Indication, 2016

Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2016

Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2016

Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2016

Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2016

Bristol-Myers Squibb Company - Partnered Products/ Combination Treatment Modalities, 2016

Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2016

Bristol-Myers Squibb Company - Out-Licensed Products/ Combination Treatment Modalities, 2016

Bristol-Myers Squibb Company - Pre-Registration, 2016

Bristol-Myers Squibb Company - Filing rejected/Withdrawn, 2016

Bristol-Myers Squibb Company - Phase III, 2016

Bristol-Myers Squibb Company - Phase II, 2016

Bristol-Myers Squibb Company - Phase I, 2016

Bristol-Myers Squibb Company - IND/CTA Filed, 2016

Bristol-Myers Squibb Company - Preclinical, 2016

Bristol-Myers Squibb Company - Discovery, 2016

Bristol-Myers Squibb Company - Pipeline by Target, 2016

Bristol-Myers Squibb Company - Pipeline by Route of Administration, 2016

Bristol-Myers Squibb Company - Pipeline by Molecule Type, 2016

Bristol-Myers Squibb Company - Pipeline Products by Mechanism of Action, 2016

Bristol-Myers Squibb Company - Recent Pipeline Updates, 2016

Bristol-Myers Squibb Company - Dormant Developmental Projects,2016

Bristol-Myers Squibb Company - Discontinued Pipeline Products, 2016

Bristol-Myers Squibb Company, Other Locations

Bristol-Myers Squibb Company, Subsidiaries

Bristol-Myers Squibb Company, Key Manufacturing Facilities

List of Figures

Bristol-Myers Squibb Company - Pipeline by Top 10 Indication, 2016

Bristol-Myers Squibb Company - Pipeline by Stage of Development, 2016

Bristol-Myers Squibb Company - Monotherapy Products in Pipeline, 2016

Bristol-Myers Squibb Company - Combination Treatment Modalities in Pipeline, 2016

Bristol-Myers Squibb Company - Partnered Products in Pipeline, 2016

Bristol-Myers Squibb Company - Out-Licensed Products in Pipeline, 2016

Bristol-Myers Squibb Company - Pipeline by Top 10 Target, 2016

Bristol-Myers Squibb Company - Pipeline by Route of Administration, 2016

Bristol-Myers Squibb Company - Pipeline by Molecule Type, 2016

Bristol-Myers Squibb Company - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll